Abstract
Liver histology retains an essential role in the diagnosis and management of patients with primary liver tumour. It is complemented but cannot be replaced by molecular techniques. The role of liver biopsy differs depending on the clinical context. Liver biopsy has been almost entirely replaced by imaging, for the diagnosis of early hepatocellular carcinoma in patients with advanced stage chronic liver disease (cirrhosis), although a return to histological diagnosis has been advocated. Liver biopsy retains a critical role in the histological diagnosis of hepatocellular adenoma and hepatocellular carcinoma arising in patients with early stage chronic liver disease or normal/near-normal liver and in the diagnosis of intrahepatic cholangiocarcinoma. The term “hepatocellular neoplasm of uncertain malignant potential” has been proposed in those instances in which it is not possible to differentiate between hepatocellular adenoma and hepatocellular carcinoma. The diagnosis of combined (or mixed) hepatocellular-cholangiocarcinoma remains challenging particularly on liver biopsy. The differential diagnosis between intrahepatic cholangiocarcinoma and metastatic adenocarcinoma requires often close clinico-pathological correlation and should not be based exclusively on immunohistochemistry. Intraoperative histological examination is critical to guide surgical intervention. It is routinely used to assess clearance of resection margins particularly for hilar cholangiocarcinoma. Histological examination of surgically resected specimens is essential to confirm the preoperative diagnosis and assess the effect of previous therapies and for prognosis in both hepatocellular and cholangiocellular tumours.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Fletcher CDM. Diagnostic histopathology of tumors. 4th ed. Edinburgh: Churchill Livingstone; 2013.
Hytiroglou P, Snover DC, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, et al. Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol. 2012;137(1):5–9.
Mullhaupt B, Durand F, Roskams T, Dutkowski P, Heim M. Is tumor biopsy necessary? Liver Transpl. 2011;17(Suppl 2):S14–25.
Heimbach JK, Kulik LM, Finn R, Sirlin CB, Abecassis M, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017;67(1):358–80.
Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152(4):745–61.
Torbenson M, Schirmacher P. Liver cancer biopsy–back to the future?! Hepatology. 2015;61(2):431–3.
Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis. 2010;42(5):341–7.
Balabaud C, Bioulac-Sage P, Ferrell L, Kakar S, Paradis V, Quaglia A, et al. Well-differentiated hepatocellular neoplasm of uncertain malignant potential. Hum Pathol. 2015;46(4):634–5.
Bedossa P, Burt AD, Brunt EM, Callea F, Clouston AD, Dienes HP, et al. Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category. Hum Pathol. 2014;45(3):658–60.
Clayton EF, Malik S, Bonnel A, Mu Y, Olthoff K, Shaked A, et al. Liver transplantation and cirrhotomimetic hepatocellular carcinoma: classification and outcomes. Liver Transpl. 2014;20(7):765–74.
Zen C, Zen Y, Mitry RR, Corbeil D, Karbanova J, O'Grady J, et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl. 2011;17(8):943–54.
Calderaro J, Nault JC, Balabaud C, Couchy G, Saint-Paul MC, Azoulay D, et al. Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. Mod Pathol. 2016;29(1):43–50.
Quaglia A, Tibballs J, Grasso A, Prasad N, Nozza P, Davies SE, et al. Focal nodular hyperplasia-like areas in cirrhosis. Histopathology. 2003;42(1):14–21.
Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouze E, Blanc JF, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67(4):727–38.
Nakanuma Y, Sudo Y. Biliary tumors with pancreatic counterparts. Semin Diagn Pathol. 2017;34(2):167–75.
Zen Y, Quaglia A, Heaton N, Rela M, Portmann B. Two distinct pathways of carcinogenesis in primary sclerosing cholangitis. Histopathology. 2011;59(6):1100–10.
Komuta M, Govaere O, Vandecaveye V, Akiba J, Van Steenbergen W, Verslype C, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology. 2012;55(6):1876–88.
Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016;64(4):1178–88.
Zen Y, Britton D, Mitra V, Pike I, Sarker D, Itoh T, et al. Tubulin beta-III: a novel immunohistochemical marker for intrahepatic peripheral cholangiocarcinoma. Histopathology. 2014;65(6):784–92.
Moreno Luna LE, Kipp B, Halling KC, Sebo TJ, Kremers WK, Roberts LR, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology. 2006;131(4):1064–72.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Quaglia, A. (2019). The Role of Histology in Hepatocellular and Cholangiocarcinoma. In: Cross, T., Palmer, D. (eds) Liver Cancers. Springer, Cham. https://doi.org/10.1007/978-3-319-92216-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-92216-4_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92215-7
Online ISBN: 978-3-319-92216-4
eBook Packages: MedicineMedicine (R0)